Amgen says new data to be presented at ASH 2017
Amgen announced that new clinical data and analyses from 33 abstracts, including six oral presentations, evaluating approved medicines and investigational immuno-oncology agents from the company's robust hematology portfolio and pipeline will be presented at the 59th American Society of Hematology Annual Meeting & Exposition in Atlanta, Dec. 9-12, 2017. The breadth and depth of data to be presented at ASH highlight Amgen's commitment to advancing treatment options for patients with some of the most difficult-to-treat blood cancers and disorders. Notably at ASH, positive overall survival results from the Phase 3 ASPIRE trial will be detailed for the first time in an oral presentation, which showed the addition of KYPROLIS to lenalidomide and dexamethasone significantly extended OS versus lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The safety data from ASPIRE was consistent with the known safety profile of KYPROLIS.